

03CO
#B
PATENT
Docket No. 2710-4007 US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Michael B. CHANCELLOR and Group Art Unit: To Be Assigned
Johnny HUARD
Serial No. : 09/302,896 Examiner: To Be Assigned
Filed : April 30, 1999
For : Muscle-Derived Cell Mediated Gene Delivery for Treating Muscle- or Bone-Related Injury or Dysfunction

EXPRESS MAIL CERTIFICATE

Express Mail Label No. EJ 854 034 503 US

Date of Deposit: August 16, 1999

I hereby certify that the following attached paper(s) and/or fee

1. Information Disclosure Statement Transmittal
2. Information Disclosure Statement
3. PTO 1449 Form with 25 listed references
4. Copies of 25 listed references
5. Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37

C.F.R. §1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington,

D.C. 20231.

Gilberto Soto, Jr.

(Typed or printed name of person mailing papers and/or fee)

(Signature of person mailing papers and/or fee)

CORRESPONDENCE ADDRESS:


MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, New York 10154

(212) 758-4800

(212) 751-6849 Facsimile



PATENT
Docket No.: 2710-4007US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michael B. CHANCELLOR and Johnny HUARD
Serial No. : 09/302,896
Filed : April 30, 1999
For : **Muscle-Derived Cell Mediated Gene Delivery for Treating
Muscle- or Bone-Related Injury or Dysfunction**
Group Art
Unit : To be assigned
Examiner : To be assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Sir:

Transmitted herewith for filing in the above-identified patent application is an Information Disclosure Statement, PTO 1449 form listing 25 references and copies of the 25 listed references.

No fee is believed to be due for the filing of this Information Disclosure Statement. However, should any fee(s) be properly assessable for this submission, the Assistant Commissioner is hereby authorized to charge any additional fee(s) which may

485512_1

EJ 854 034 503 US

Docket No.: 2710-4007US1

be required to Deposit Account No. 13-4500, Order No. 2710-4007US1. **A duplicate copy of this sheet is attached.**

Respectfully submitted,


MORGAN & FINNEGAN, L.L.P.

Dated: August 16, 1999

By: Leslie A. Serunian
Leslie A. Serunian
Registration No. 35,353

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154-0053
(212) 758-4800 (Telephone)
(212) 751-6849 (Facsimile)



PATENT

Docket No. 2710-4007US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Michael B. CHANCELLOR and Johnny HUARD Group Art Unit: To be assigned

Serial No : 09/302,896 Examiner: To be assigned

Filed : April 30, 1999

For : MUSCLE-DERIVED CELL MEDIATED GENE DELIVERY FOR TREATING
MUSCLE- AND BONE-RELATED INJURY OR DYSFUNCTION

INFORMATION DISCLOSURE STATEMENT

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application for filing date of the continued prosecution application filed on _____; or
 - ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
 - ☒ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☐ A check in the amount of \$240.00 is enclosed in payment of the fee.
 - ☐ Charge the fee to Deposit Account No. 13-4500. Order No. _____. A
DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. ☐ one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
 - b. ☐ the attached petition requesting consideration of this Information Disclosure Statement; and
 - c. ☐ the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.
8. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
 - b. ☐ 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To withdraw Application From Issue.
 - c. ☐ The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.

9. ☐ I hereby certify that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

☐ I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after make reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

10. ☐ A check in the amount of \$130.00 is enclosed in payment of the fee due under C.F.R. §1.17(i)(1).

☐ Charge the fee due under C.F.R. §1.17(i)(1) to Deposit Account No. 13-4500. Order No. _____ A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500. Order No. 2710-4007US1. **A DUPLICATE COPY OF THIS SHEET IS ATTACHED.**

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: August 16, 1999

By: Leslie A. Serunian
Leslie A. Serunian
Registration No. 35,353

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Facsimile

FORM: IDS.NY
Rev. 05/26/98